Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.34 Billion31.01% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.18MShares$280 Million11.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$229 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.78MShares$187 Million4.39% of portfolio
-
Black Rock Inc. New York, NY2.71MShares$182 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$181 Million30.59% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.92MShares$129 Million23.03% of portfolio
-
State Street Corp Boston, MA1.51MShares$102 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.49MShares$99.8 Million9.65% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.44MShares$96.4 Million18.4% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 28
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.28%
|
$134,000
$67.77 P/Share
|
|
May 15
2024
|
Emily Conley |
SELL
Open market or private sale
|
Direct |
5,000
-99.84%
|
$345,000
$69.09 P/Share
|
|
May 15
2024
|
Emily Conley |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+44.92%
|
$55,000
$11.58 P/Share
|
|
May 13
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-0.86%
|
$2,475,000
$66.13 P/Share
|
|
May 06
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-1.26%
|
$2,587,500
$69.77 P/Share
|
|
May 02
2024
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.82%
|
$216,000
$72.42 P/Share
|
|
May 02
2024
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+7.63%
|
$18,000
$6.89 P/Share
|
|
Apr 29
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.28%
|
$134,000
$67.8 P/Share
|
|
Apr 29
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-0.82%
|
$2,512,500
$67.8 P/Share
|
|
Apr 22
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-0.8%
|
$2,362,500
$63.66 P/Share
|
|
Apr 15
2024
|
Emily Conley |
SELL
Open market or private sale
|
Direct |
5,000
-71.29%
|
$330,000
$66.09 P/Share
|
|
Apr 15
2024
|
Emily Conley |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.96%
|
$45,000
$9.36 P/Share
|
|
Apr 15
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-1.17%
|
$2,437,500
$65.72 P/Share
|
|
Apr 08
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-0.76%
|
$2,550,000
$68.72 P/Share
|
|
Apr 04
2024
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.12%
|
$219,000
$73.2 P/Share
|
|
Apr 04
2024
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+7.63%
|
$18,000
$6.89 P/Share
|
|
Apr 01
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
37,500
-1.12%
|
$2,887,500
$77.01 P/Share
|
|
Mar 28
2024
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
22,000
-14.73%
|
$1,650,000
$75.13 P/Share
|
|
Mar 28
2024
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+17.96%
|
$506,000
$23.39 P/Share
|
|
Mar 27
2024
|
Andrew A. F. Hack |
SELL
Open market or private sale
|
Indirect |
880,000
-12.58%
|
$65,120,000
$74.59 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 246K shares |
|---|---|
| Exercise of conversion of derivative security | 305K shares |
| Open market or private sale | 1.71M shares |
|---|